TXMD News and Press, TherapeuticsMD Inc.

2024-06-28 11:52:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips TherapeuticsMD (NASDAQ: TXMD ) just reported results for the fourth quarter of 2023. TherapeuticsMD reported earnings per share of -14 cents. The company reported reve...

2024-05-30 16:55:01 ET In its annual 2024 Russell index reconstitution, about 213 companies will be added and 198 deleted from the Russell Microcap Index. Read the full article on Seeking Alpha For further details see: Nektar, Verastem among healthcare additions in Russe...

2024-05-10 16:17:14 ET More on Therapeutics MD Therapeutics MD reports FY results Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics MD GAAP EPS of -$0.07

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...

2024-03-29 16:21:11 ET More on Therapeutics MD Financial information for Therapeutics MD Read the full article on Seeking Alpha For further details see: Therapeutics MD reports FY results

• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...

2023-11-14 17:29:17 ET More on Therapeutics MD Seeking Alpha’s Quant Rating on Therapeutics MD Financial information for Therapeutics MD For further details see: TherapeuticsMD exploring strategic alternatives for company

2023-11-14 16:42:42 ET More on Therapeutics MD Seeking Alpha’s Quant Rating on Therapeutics MD Financial information for Therapeutics MD For further details see: Therapeutics MD GAAP EPS of -$0.13

Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical ro...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...